<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00988143</url>
  </required_header>
  <id_info>
    <org_study_id>GRC43</org_study_id>
    <secondary_id>UTN: U1111-1111-5427</secondary_id>
    <nct_id>NCT00988143</nct_id>
  </id_info>
  <brief_title>A Study of Influenza Virus Vaccines in Children and Adults</brief_title>
  <official_title>Immunogenicity and Safety Among Children and Adults of the 2009-2010 Trivalent Influenza Vaccine, 2008-2009 Trivalent Influenza Vaccine, and Quadrivalent Influenza Vaccine (Intramuscular Route)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sanofi Pasteur, a Sanofi Company</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sanofi</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to describe the immunogenicity of the prototype Quadrivalent
      Influenza Vaccine (QIV) compared with the 2009-2010 Trivalent Influenza Vaccine (TIV) and the
      2008-2009 TIV among children and adults.

      Primary Objective:

      To describe the immunogenicity of the prototype Quadrivalent Influenza Vaccine (QIV) compared
      with the 2009-2010 Trivalent Influenza Vaccine (TIV) and the 2008-2009 TIV among adults.

      Observational Objectives:

        -  To describe the safety of the 2009-2010 TIV among subjects ≥6 months to &lt;5 years, 18-60
           years, and ≥ 61 years of age, and to describe the safety of 2008-2009 TIV and prototype
           QIV Fluzone® vaccines among subjects 18-60 years and ≥ 61 years of age.

        -  To describe the immunogenicity of the 2009-2010 TIV vaccine among subjects ≥6 months to
           &lt;5 years, 18-60 years, and ≥61 years of age, and to describe the immunogenicity of
           2008-2009 TIV and prototype QIV vaccines among subjects 18-60 years and ≥61 years of
           age.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>October 2009</start_date>
  <completion_date type="Actual">March 2010</completion_date>
  <primary_completion_date type="Actual">December 2009</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants Reporting Solicited Injection Site and Systemic Reactions Following Vaccination With Quadrivalent Influenza Vaccine or Fluzone® Trivalent Influenza Vaccines.</measure>
    <time_frame>Day 0 up to 7 days post-vaccination</time_frame>
    <description>Solicited injection site reactions (6-23 Months): Tenderness, Redness and Swelling; Solicited systemic reactions: Fever, Abnormal crying, Drowsiness, Loss of appetite, Vomiting and Irritability Grade 3 Tenderness: cries when injected limb is moved; Redness and Swelling: ≥5 cm; Fever: &gt;103.1°F; Abnormal crying: &gt;3 hours; Drowsiness: Sleeping most of the time; Loss of appetite: refuses ≥3 feeds/meals; Vomiting: ≥6 episodes/24 hours; Irritability: inconsolable.
(24-59 Months): Pain, Redness and Swelling; Fever, Headache, Malaise and Myalgia. Grade 3: Pain, Incapacitating; Redness and Swelling: ≥5 cm; Fever: &gt;102.1°F, Headache, Malaise and Myalgia: Significant, prevents daily activity.
(Adults): Pain, Redness, Induration, and Ecchymosis; Fever, Headache, Malaise, Myalgia and Shivering.
Grade 3: Pain: significant, prevents daily activities; Redness, Swelling, Induration and Ecchymosis: &gt;10 cm; Fever &gt;102.1°F; Headache, Malaise, Myalgia &amp; Shivering: Significant, prevents daily activity.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Geometric Mean Titers (GMTs) Against Influenza B Strains After Vaccination With Fluzone® Quadrivalent Influenza Vaccine or Trivalent Influenza Vaccine in Adult Participants.</measure>
    <time_frame>21 Days post last vaccination</time_frame>
    <description>Immunogenicity outcomes were assessed in serum samples by Hemagglutination inhibition (HAI) assay. The lower limit of quantitation (LLOQ) was set at the lowest dilution used in the assay, 1/10. Titers below this level were reported as &lt;10.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Geometric Mean Titers (GMTs) Against Influenza A Strains After Vaccination With Fluzone® Quadrivalent Influenza Vaccine or Trivalent Influenza Vaccine in Adult Participants.</measure>
    <time_frame>21 Days post last vaccination</time_frame>
    <description>Immunogenicity outcomes were assessed in serum samples by Hemagglutination inhibition (HAI) assay. The lower limit of quantitation (LLOQ) was set at the lowest dilution used in the assay, 1/10. Titers below this level were reported as &lt;10.</description>
  </primary_outcome>
  <other_outcome>
    <measure>Number of Adult Participants With Seroprotection Against Influenza Vaccine Antigens Following Vaccination With Fluzone® Quadrivalent Influenza Vaccine or Trivalent Influenza Vaccine</measure>
    <time_frame>Day 0 (pre-vaccination) and Day 21 post final vaccination</time_frame>
    <description>Immunogenicity outcomes were assessed in serum samples by HAI assay. The lower limit of quantitation (LLOQ) was set at the lowest dilution used in the assay, 1/10. Titers below this level were reported as &lt;10.
Seroprotection to vaccine antigens was defined as a pre-vaccination and post-vaccination titer value of titer ≥ 40 (1/dil)</description>
  </other_outcome>
  <other_outcome>
    <measure>Geometric Mean Titers Against the Influenza Vaccine Antigens After Vaccination With Fluzone® Quadrivalent Influenza Vaccine or Trivalent Influenza Vaccines in Adult Participants</measure>
    <time_frame>21 Days post last vaccination</time_frame>
    <description>Immunogenicity outcomes were assessed in serum samples by HAI assay. The lower limit of quantitation (LLOQ) was set at the lowest dilution used in the assay, 1/10. Titers below this level were reported as &lt;10.</description>
  </other_outcome>
  <other_outcome>
    <measure>Number of Adult Participants With Seroconversion to Vaccine Antigens Following Vaccination With Fluzone® Quadrivalent Influenza Vaccine or Trivalent Influenza Vaccines</measure>
    <time_frame>Day 21 post-vaccination</time_frame>
    <description>Seroconversion to vaccine antigens was defined as a pre-vaccination titer &lt; 10 (1/dil) and a post-vaccination titer ≥ 40 (1/dil), or a pre-vaccination titer ≥ 10 (1/dil) and a ≥ 4-fold increase in post-vaccination titer.</description>
  </other_outcome>
  <other_outcome>
    <measure>Geometric Mean Titers Against the Influenza Vaccine Antigens After Vaccination With Fluzone® Quadrivalent Influenza Vaccine or Trivalent Influenza Vaccines in All Study Participants</measure>
    <time_frame>21 Days post last vaccination</time_frame>
    <description>Immunogenicity outcomes were assessed in serum samples by HAI assay. The lower limit of quantitation (LLOQ) was set at the lowest dilution used in the assay, 1/10. Titers below this level were reported as &lt;10.</description>
  </other_outcome>
  <other_outcome>
    <measure>Number of Participants With Seroconversion to Influenza Vaccine Antigens Following Vaccination With Fluzone® Quadrivalent Influenza Vaccine or Trivalent Influenza Vaccines</measure>
    <time_frame>Day 0 up to 21 days post-vaccination</time_frame>
    <description>Seroconversion to vaccine antigens were defined as a pre-vaccination titer &lt; 10 (1/dil) and a post-vaccination titer ≥ 40 (1/dil), or a pre-vaccination titer ≥ 10 (1/dil) and a ≥ 4-fold increase in post-vaccination titer.</description>
  </other_outcome>
  <other_outcome>
    <measure>Number of Participants With Seroprotection to Influenza Vaccine Antigens Following Vaccination With Fluzone® Quadrivalent Influenza Vaccine or Trivalent Influenza Vaccines</measure>
    <time_frame>Day 0 (pre-vaccination) and Day 21 post final vaccination</time_frame>
    <description>Immunogenicity outcomes were assessed in serum samples by HAI assay. The lower limit of quantitation (LLOQ) was set at the lowest dilution used in the assay, 1/10. Titers below this level were reported as &lt;10.
Seroprotection to vaccine antigens was defined as a pre-vaccination and post-vaccination titer value of titer ≥ 40 (1/dil).</description>
  </other_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">600</enrollment>
  <condition>Influenza</condition>
  <arm_group>
    <arm_group_label>Study Group 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive the 2009-2010 Trivalent Influenza Vaccine (TIV) (Pediatric dose have no preservatives)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Study Group 2</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Participants will receive the 2008-2009 Trivalent Influenza Vaccine (TIV)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Study Group 3</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Participants will receive the Quadrivalent Influenza Vaccine (QIV)</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>2009-2010 Trivalent Influenza Virus Vaccine</intervention_name>
    <description>0.25 mL, Intramuscular (participants at 6 to 35 months of age - Pediatric Dose); Others 0.5 mL, Intramuscular.</description>
    <arm_group_label>Study Group 1</arm_group_label>
    <other_name>Fluzone®</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>2008-2009 Trivalent Influenza Virus Vaccine</intervention_name>
    <description>0.25 mL, Intramuscular; 0.5 mL, Intramuscular.</description>
    <arm_group_label>Study Group 2</arm_group_label>
    <other_name>Fluzone®</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Quadrivalent Influenza Virus Vaccine</intervention_name>
    <description>0.5 mL, Intramuscular</description>
    <arm_group_label>Study Group 3</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria :

          -  Subject is ≥ 6 months to &lt; 5 years of age or 18 years of age or older on the day of
             inclusion.

          -  Parent/legal guardian (if the subject is ≥ 6 months to &lt; 5 years of age) or adult
             subject (if 18 years of age or older) is willing and able to attend scheduled visits
             and to comply with the study procedures during the entire duration of the study.

          -  Subject in reasonably good health as assessed by the Investigator.

          -  Parent/legal guardian (if the subject is ≥ 6 months to &lt; 5 years of age) or adult
             subject (if 18 years of age or older) is willing and able to give informed consent.

          -  For subjects ≥ 6 months to &lt; 5 years of age: subject was born at full term of
             pregnancy (≥ 37 weeks) with a birth weight ≥ 2.5 kg (5.5 lbs).

          -  For a woman, inability to bear a child or negative serum/urine pregnancy test, if
             applicable.

        Exclusion Criteria :

        For all subjects:

          -  History of allergy to egg proteins, chicken proteins, or one of the constituents of
             the vaccine, such as thimerosal or formaldehyde.

          -  History of serious adverse reaction to any influenza vaccine.

          -  Laboratory-confirmed influenza infection or vaccination against influenza in the six
             months preceding enrollment in the study.

          -  Any vaccination scheduled between Visit 1 and Visit 2 or Visit 3.

          -  Participation in any other interventional drug or vaccine trial during participation
             in this study.

          -  Thrombocytopenia or bleeding disorder contraindicating intramuscular vaccination.

          -  Any condition that in the opinion of the Investigator would pose a health risk to the
             subject if enrolled or could interfere with the evaluation of the vaccine.

          -  Prior personal history of Guillain-Barré syndrome.

        For subjects &gt; 6 months to &lt; 5 years of age:

          -  Known or suspected impairment of immunologic function or receipt of immunosuppressive
             therapy or immunoglobulin since birth.

          -  Personal or immediate family history of congenital immune deficiency.

          -  Developmental delay, neurologic disorder, or seizure disorder.

          -  Chronic medical, congenital, or developmental disorder.

          -  Known HIV-positive mother.

        For subjects 18 years of age and older:

          -  Immunocompromising condition; immunosuppressive therapy (including systemic steroid
             use for two weeks or more); cancer chemotherapy or radiation therapy at the time of
             enrollment, planned during the period of this study, or at any time within the past
             six months.

          -  Diabetes mellitus requiring pharmacological control.

          -  Person deprived of freedom by an administrative or court order (having legal or
             medical guardian).

          -  For women of childbearing potential, a positive urine pregnancy test, breast feeding,
             or not using a medically approved and reliable form of contraception (oral
             contraceptives or double barrier method) for the duration of the trial.

          -  Current use of alcohol or recreational drugs that may interfere with the subject's
             ability to comply with trial procedures.

          -  Any subject with the following conditions is not eligible for enrollment. However, the
             subject may be enrolled subsequently if the condition has resolved and enrollment is
             still ongoing and the subject meets all other inclusion/exclusion criteria:

               -  An acute illness with or without fever in the 72 hours preceding enrollment in
                  the trial.

               -  Clinically significant findings in vital signs or review of systems (Investigator
                  judgment).

               -  Received any vaccinations within the preceding 14 days.

               -  Participation in any other interventional clinical trial within 30 days prior to
                  enrollment.

               -  Receipt of blood or blood products within the three months preceding enrollment
                  in the study.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>6 Months</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Director</last_name>
    <role>Study Director</role>
    <affiliation>Sanofi Pasteur Inc.</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27704</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45249</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Jefferson Hills</city>
        <state>Pennsylvania</state>
        <zip>15025</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Norfolk</city>
        <state>Virginia</state>
        <zip>23507</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.sanofipasteur.com</url>
  </link>
  <link>
    <url>http://www.sanofiaventis.com</url>
  </link>
  <verification_date>November 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 1, 2009</study_first_submitted>
  <study_first_submitted_qc>October 1, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 2, 2009</study_first_posted>
  <results_first_submitted>July 3, 2013</results_first_submitted>
  <results_first_submitted_qc>November 18, 2013</results_first_submitted_qc>
  <results_first_posted type="Estimate">December 12, 2013</results_first_posted>
  <disposition_first_submitted>January 3, 2011</disposition_first_submitted>
  <disposition_first_submitted_qc>January 3, 2011</disposition_first_submitted_qc>
  <disposition_first_posted type="Estimate">January 5, 2011</disposition_first_posted>
  <last_update_submitted>November 18, 2013</last_update_submitted>
  <last_update_submitted_qc>November 18, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 12, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Influenza</keyword>
  <keyword>Trivalent Influenza Virus Vaccine</keyword>
  <keyword>Quadrivalent Influenza Virus Vaccine</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Influenza, Human</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vaccines</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>The study participants were enrolled from 01 October through 05 November 2009 in 4 clinical centers in the US.</recruitment_details>
      <pre_assignment_details>A total of 600 participants who met all the inclusion criteria and none of the exclusion criteria were enrolled, randomized and vaccinated in the study.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Study Group 1 (2009-2010 TIV)</title>
          <description>Participants received the 2009-2010 Trivalent Influenza Vaccine (Pediatric dose with no preservatives)</description>
        </group>
        <group group_id="P2">
          <title>Study Group 2 (2008-2009 TIV)</title>
          <description>Participants received the 2008-2009 Trivalent Influenza Vaccine</description>
        </group>
        <group group_id="P3">
          <title>Study Group 3 (QIV)</title>
          <description>Participants received the Quadrivalent Influenza Vaccine</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="220"/>
                <participants group_id="P2" count="190"/>
                <participants group_id="P3" count="190"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="220"/>
                <participants group_id="P2" count="190"/>
                <participants group_id="P3" count="190"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Study Group 1 (2009-2010 Trivalent Influenza Vaccine)</title>
          <description>Participants received the 2009-2010 Trivalent Influenza Vaccine (TIV)</description>
        </group>
        <group group_id="B2">
          <title>Study Group 2 (2008-2009 Trivalent Influenza Vaccine)</title>
          <description>Participants received the 2008-2009 Trivalent Influenza Vaccine (TIV)</description>
        </group>
        <group group_id="B3">
          <title>Study Group 3 (Quadrivalent Influenza Vaccine)</title>
          <description>Participants received the Quadrivalent Influenza Vaccine (QIV)</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="220"/>
            <count group_id="B2" value="190"/>
            <count group_id="B3" value="190"/>
            <count group_id="B4" value="600"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="30"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="127"/>
                    <measurement group_id="B2" value="135"/>
                    <measurement group_id="B3" value="123"/>
                    <measurement group_id="B4" value="385"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="63"/>
                    <measurement group_id="B2" value="55"/>
                    <measurement group_id="B3" value="67"/>
                    <measurement group_id="B4" value="185"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>Years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="47.8" spread="24.9"/>
                    <measurement group_id="B2" value="54.9" spread="17.5"/>
                    <measurement group_id="B3" value="56.7" spread="17.2"/>
                    <measurement group_id="B4" value="52.9" spread="20.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="144"/>
                    <measurement group_id="B2" value="124"/>
                    <measurement group_id="B3" value="130"/>
                    <measurement group_id="B4" value="398"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="76"/>
                    <measurement group_id="B2" value="66"/>
                    <measurement group_id="B3" value="60"/>
                    <measurement group_id="B4" value="202"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>Participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="220"/>
                    <measurement group_id="B2" value="190"/>
                    <measurement group_id="B3" value="190"/>
                    <measurement group_id="B4" value="600"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants Reporting Solicited Injection Site and Systemic Reactions Following Vaccination With Quadrivalent Influenza Vaccine or Fluzone® Trivalent Influenza Vaccines.</title>
        <description>Solicited injection site reactions (6-23 Months): Tenderness, Redness and Swelling; Solicited systemic reactions: Fever, Abnormal crying, Drowsiness, Loss of appetite, Vomiting and Irritability Grade 3 Tenderness: cries when injected limb is moved; Redness and Swelling: ≥5 cm; Fever: &gt;103.1°F; Abnormal crying: &gt;3 hours; Drowsiness: Sleeping most of the time; Loss of appetite: refuses ≥3 feeds/meals; Vomiting: ≥6 episodes/24 hours; Irritability: inconsolable.
(24-59 Months): Pain, Redness and Swelling; Fever, Headache, Malaise and Myalgia. Grade 3: Pain, Incapacitating; Redness and Swelling: ≥5 cm; Fever: &gt;102.1°F, Headache, Malaise and Myalgia: Significant, prevents daily activity.
(Adults): Pain, Redness, Induration, and Ecchymosis; Fever, Headache, Malaise, Myalgia and Shivering.
Grade 3: Pain: significant, prevents daily activities; Redness, Swelling, Induration and Ecchymosis: &gt;10 cm; Fever &gt;102.1°F; Headache, Malaise, Myalgia &amp; Shivering: Significant, prevents daily activity.</description>
        <time_frame>Day 0 up to 7 days post-vaccination</time_frame>
        <population>Solicited injection site and systemic reactions were assessed in all randomized and vaccinated participants, safety population.</population>
        <group_list>
          <group group_id="O1">
            <title>Study Group 1 (2009-2010 Trivalent Influenza Vaccine)</title>
            <description>Participants received the 2009-2010 Trivalent Influenza Vaccine (TIV)</description>
          </group>
          <group group_id="O2">
            <title>Study Group 2 (2008-2009 Trivalent Influenza Vaccine)</title>
            <description>Participants received the 2008-2009 Trivalent Influenza Vaccine (TIV)</description>
          </group>
          <group group_id="O3">
            <title>Study Group 3 (Quadrivalent Influenza Vaccine)</title>
            <description>Participants received the Quadrivalent Influenza Vaccine (QIV)</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Reporting Solicited Injection Site and Systemic Reactions Following Vaccination With Quadrivalent Influenza Vaccine or Fluzone® Trivalent Influenza Vaccines.</title>
          <description>Solicited injection site reactions (6-23 Months): Tenderness, Redness and Swelling; Solicited systemic reactions: Fever, Abnormal crying, Drowsiness, Loss of appetite, Vomiting and Irritability Grade 3 Tenderness: cries when injected limb is moved; Redness and Swelling: ≥5 cm; Fever: &gt;103.1°F; Abnormal crying: &gt;3 hours; Drowsiness: Sleeping most of the time; Loss of appetite: refuses ≥3 feeds/meals; Vomiting: ≥6 episodes/24 hours; Irritability: inconsolable.
(24-59 Months): Pain, Redness and Swelling; Fever, Headache, Malaise and Myalgia. Grade 3: Pain, Incapacitating; Redness and Swelling: ≥5 cm; Fever: &gt;102.1°F, Headache, Malaise and Myalgia: Significant, prevents daily activity.
(Adults): Pain, Redness, Induration, and Ecchymosis; Fever, Headache, Malaise, Myalgia and Shivering.
Grade 3: Pain: significant, prevents daily activities; Redness, Swelling, Induration and Ecchymosis: &gt;10 cm; Fever &gt;102.1°F; Headache, Malaise, Myalgia &amp; Shivering: Significant, prevents daily activity.</description>
          <population>Solicited injection site and systemic reactions were assessed in all randomized and vaccinated participants, safety population.</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="220"/>
                <count group_id="O2" value="190"/>
                <count group_id="O3" value="190"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Injection site Tenderness (15, 0, 0)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="0" lower_limit="0" upper_limit="0"/>
                    <measurement group_id="O3" value="0" lower_limit="0" upper_limit="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 Injection site Tenderness (15, 0, 0)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0" lower_limit="0" upper_limit="0"/>
                    <measurement group_id="O3" value="0" lower_limit="0" upper_limit="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Injection site Pain (205, 190, 190)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="105"/>
                    <measurement group_id="O2" value="82" lower_limit="0" upper_limit="0"/>
                    <measurement group_id="O3" value="90" lower_limit="0" upper_limit="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 Injection site Pain (206, 190, 190)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0" lower_limit="0" upper_limit="0"/>
                    <measurement group_id="O3" value="1" lower_limit="0" upper_limit="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Injection site Erythema (220, 190, 190)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7"/>
                    <measurement group_id="O2" value="3" lower_limit="0" upper_limit="0"/>
                    <measurement group_id="O3" value="2" lower_limit="0" upper_limit="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 Injection site Erythema (220, 190, 190)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0" lower_limit="0" upper_limit="0"/>
                    <measurement group_id="O3" value="0" lower_limit="0" upper_limit="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Injection site Swelling (220, 190, 190)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10"/>
                    <measurement group_id="O2" value="2" lower_limit="0" upper_limit="0"/>
                    <measurement group_id="O3" value="1" lower_limit="0" upper_limit="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 Injection site Swelling (220, 190, 190)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0" lower_limit="0" upper_limit="0"/>
                    <measurement group_id="O3" value="0" lower_limit="0" upper_limit="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Injection site Induration (190, 190, 190)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="1" lower_limit="0" upper_limit="0"/>
                    <measurement group_id="O3" value="1" lower_limit="0" upper_limit="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 Injection site Induration (190, 190, 190)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0" lower_limit="0" upper_limit="0"/>
                    <measurement group_id="O3" value="0" lower_limit="0" upper_limit="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Injection site Ecchymosis (190, 190, 190)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="1" lower_limit="0" upper_limit="0"/>
                    <measurement group_id="O3" value="1" lower_limit="0" upper_limit="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 Injection site Ecchymosis (190, 190, 190)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0" lower_limit="0" upper_limit="0"/>
                    <measurement group_id="O3" value="0" lower_limit="0" upper_limit="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fever (220, 190, 190)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="1" lower_limit="0" upper_limit="0"/>
                    <measurement group_id="O3" value="0" lower_limit="0" upper_limit="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 Fever (220, 190, 190)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0" lower_limit="0" upper_limit="0"/>
                    <measurement group_id="O3" value="0" lower_limit="0" upper_limit="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Vomiting (15, 0, 0)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0" lower_limit="0" upper_limit="0"/>
                    <measurement group_id="O3" value="0" lower_limit="0" upper_limit="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 Vomiting (15, 0, 0)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0" lower_limit="0" upper_limit="0"/>
                    <measurement group_id="O3" value="0" lower_limit="0" upper_limit="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Malaise (205, 190, 190)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="30"/>
                    <measurement group_id="O2" value="23" lower_limit="0" upper_limit="0"/>
                    <measurement group_id="O3" value="20" lower_limit="0" upper_limit="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 Malaise (205, 190, 190)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="1" lower_limit="0" upper_limit="0"/>
                    <measurement group_id="O3" value="2" lower_limit="0" upper_limit="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Appetite lost (15, 0, 0)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0" lower_limit="0" upper_limit="0"/>
                    <measurement group_id="O3" value="0" lower_limit="0" upper_limit="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 Appetite lost (15, 0, 0)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0" lower_limit="0" upper_limit="0"/>
                    <measurement group_id="O3" value="0" lower_limit="0" upper_limit="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Drowsiness (15, 0, 0)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="0" lower_limit="0" upper_limit="0"/>
                    <measurement group_id="O3" value="0" lower_limit="0" upper_limit="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 Drowsiness (15, 0, 0)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0" lower_limit="0" upper_limit="0"/>
                    <measurement group_id="O3" value="0" lower_limit="0" upper_limit="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Crying abnormal (15, 0, 0)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0" lower_limit="0" upper_limit="0"/>
                    <measurement group_id="O3" value="0" lower_limit="0" upper_limit="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 Crying abnormal (15, 0, 0)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0" lower_limit="0" upper_limit="0"/>
                    <measurement group_id="O3" value="0" lower_limit="0" upper_limit="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Headache (205, 189, 190)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="35"/>
                    <measurement group_id="O2" value="34" lower_limit="0" upper_limit="0"/>
                    <measurement group_id="O3" value="30" lower_limit="0" upper_limit="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 Headache (205, 189, 190)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0" lower_limit="0" upper_limit="0"/>
                    <measurement group_id="O3" value="1" lower_limit="0" upper_limit="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Irritability (15, 0, 0)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="0" lower_limit="0" upper_limit="0"/>
                    <measurement group_id="O3" value="0" lower_limit="0" upper_limit="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 Irritability (15, 0, 0)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0" lower_limit="0" upper_limit="0"/>
                    <measurement group_id="O3" value="0" lower_limit="0" upper_limit="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Myalgia (205, 190, 190)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="50"/>
                    <measurement group_id="O2" value="32" lower_limit="0" upper_limit="0"/>
                    <measurement group_id="O3" value="45" lower_limit="0" upper_limit="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 Myalgia (205, 190, 190)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0" lower_limit="0" upper_limit="0"/>
                    <measurement group_id="O3" value="0" lower_limit="0" upper_limit="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Shivering (190, 190, 190)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10"/>
                    <measurement group_id="O2" value="6" lower_limit="0" upper_limit="0"/>
                    <measurement group_id="O3" value="5" lower_limit="0" upper_limit="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 Shivering (190, 190, 190)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0" lower_limit="0" upper_limit="0"/>
                    <measurement group_id="O3" value="0" lower_limit="0" upper_limit="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Geometric Mean Titers (GMTs) Against Influenza B Strains After Vaccination With Fluzone® Quadrivalent Influenza Vaccine or Trivalent Influenza Vaccine in Adult Participants.</title>
        <description>Immunogenicity outcomes were assessed in serum samples by Hemagglutination inhibition (HAI) assay. The lower limit of quantitation (LLOQ) was set at the lowest dilution used in the assay, 1/10. Titers below this level were reported as &lt;10.</description>
        <time_frame>21 Days post last vaccination</time_frame>
        <population>Geometric mean titers to vaccine B strains were determined in randomized and vaccinated participants, per-protocol population</population>
        <group_list>
          <group group_id="O1">
            <title>Study Group 1 (2009-2010 Trivalent Influenza Vaccine)</title>
            <description>Participants received the 2009-2010 Trivalent Influenza Vaccine (TIV)</description>
          </group>
          <group group_id="O2">
            <title>Study Group 2 (2008-2009 Trivalent Influenza Vaccine)</title>
            <description>Participants received the 2008-2009 Trivalent Influenza Vaccine (TIV)</description>
          </group>
          <group group_id="O3">
            <title>Study Group 3 (Quadrivalent Influenza Vaccine)</title>
            <description>Participants received the Quadrivalent Influenza Vaccine (QIV)</description>
          </group>
        </group_list>
        <measure>
          <title>Geometric Mean Titers (GMTs) Against Influenza B Strains After Vaccination With Fluzone® Quadrivalent Influenza Vaccine or Trivalent Influenza Vaccine in Adult Participants.</title>
          <description>Immunogenicity outcomes were assessed in serum samples by Hemagglutination inhibition (HAI) assay. The lower limit of quantitation (LLOQ) was set at the lowest dilution used in the assay, 1/10. Titers below this level were reported as &lt;10.</description>
          <population>Geometric mean titers to vaccine B strains were determined in randomized and vaccinated participants, per-protocol population</population>
          <units>Titers</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="187"/>
                <count group_id="O2" value="188"/>
                <count group_id="O3" value="190"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>B/Brisbane/60/2008 (187, 0, 190)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="114" lower_limit="97.8" upper_limit="134"/>
                    <measurement group_id="O2" value="NA">B/Brisbane influenza virus antigen not in the vaccine administered to this group</measurement>
                    <measurement group_id="O3" value="101" lower_limit="85.6" upper_limit="120"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>B/Florida/04/2006 (0, 188, 190)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA">B/Florida influenza virus antigen not in the vaccine administered to this group</measurement>
                    <measurement group_id="O2" value="135" lower_limit="117" upper_limit="156"/>
                    <measurement group_id="O3" value="155" lower_limit="133" upper_limit="180"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Number of Adult Participants With Seroprotection Against Influenza Vaccine Antigens Following Vaccination With Fluzone® Quadrivalent Influenza Vaccine or Trivalent Influenza Vaccine</title>
        <description>Immunogenicity outcomes were assessed in serum samples by HAI assay. The lower limit of quantitation (LLOQ) was set at the lowest dilution used in the assay, 1/10. Titers below this level were reported as &lt;10.
Seroprotection to vaccine antigens was defined as a pre-vaccination and post-vaccination titer value of titer ≥ 40 (1/dil)</description>
        <time_frame>Day 0 (pre-vaccination) and Day 21 post final vaccination</time_frame>
        <population>Seroprotection against the influenza vaccine antigens were determined in randomized and vaccinated participants, per-protocol population.</population>
        <group_list>
          <group group_id="O1">
            <title>Study Group 1 (2009-2010 Trivalent Influenza Vaccine)</title>
            <description>Participants received the 2009-2010 Trivalent Influenza Vaccine (TIV)</description>
          </group>
          <group group_id="O2">
            <title>Study Group 2 (2008-2009 Trivalent Influenza Vaccine)</title>
            <description>Participants received the 2008-2009 Trivalent Influenza Vaccine (TIV)</description>
          </group>
          <group group_id="O3">
            <title>Study Group 3 (Quadrivalent Influenza Vaccine)</title>
            <description>Participants received the Quadrivalent Influenza Vaccine (QIV)</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Adult Participants With Seroprotection Against Influenza Vaccine Antigens Following Vaccination With Fluzone® Quadrivalent Influenza Vaccine or Trivalent Influenza Vaccine</title>
          <description>Immunogenicity outcomes were assessed in serum samples by HAI assay. The lower limit of quantitation (LLOQ) was set at the lowest dilution used in the assay, 1/10. Titers below this level were reported as &lt;10.
Seroprotection to vaccine antigens was defined as a pre-vaccination and post-vaccination titer value of titer ≥ 40 (1/dil)</description>
          <population>Seroprotection against the influenza vaccine antigens were determined in randomized and vaccinated participants, per-protocol population.</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="187"/>
                <count group_id="O2" value="188"/>
                <count group_id="O3" value="190"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>A/H1N1, Pre-vaccination (186, 188, 190)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="84"/>
                    <measurement group_id="O2" value="77" lower_limit="23.1" upper_limit="33.6"/>
                    <measurement group_id="O3" value="81" lower_limit="0" upper_limit="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>A/H1N1, Post-vaccination (187, 188, 190)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="168"/>
                    <measurement group_id="O2" value="173" lower_limit="123" upper_limit="172"/>
                    <measurement group_id="O3" value="176" lower_limit="0" upper_limit="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>A/H3N2, Pre-vaccination (186, 187, 190)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="83"/>
                    <measurement group_id="O2" value="91" lower_limit="27.7" upper_limit="43.3"/>
                    <measurement group_id="O3" value="93" lower_limit="0" upper_limit="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>A/H3N2, Post-vaccination (187, 188, 190)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="180"/>
                    <measurement group_id="O2" value="177" lower_limit="271" upper_limit="401"/>
                    <measurement group_id="O3" value="180" lower_limit="0" upper_limit="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>B/Brisbane/60/2008, Pre-vaccination (186, 0, 190)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="80"/>
                    <measurement group_id="O2" value="NA" lower_limit="0" upper_limit="0">B/Brisbane/60/2008 influenza virus antigen was not in the vaccine administered to this group.</measurement>
                    <measurement group_id="O3" value="69" lower_limit="0" upper_limit="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>B/Brisbane/60/2008, Post-vaccination (187, 0, 190)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="168"/>
                    <measurement group_id="O2" value="NA" lower_limit="0" upper_limit="0">B/Brisbane/60/2008 influenza virus antigen was not in the vaccine administered to this group.</measurement>
                    <measurement group_id="O3" value="162" lower_limit="0" upper_limit="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>B/Florida/04/2006, Pre-vaccination (0, 187, 190)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA">B/Florida/04/2006 influenza virus antigen was not in the vaccine administered to this group.</measurement>
                    <measurement group_id="O2" value="97" lower_limit="22.8" upper_limit="31.1"/>
                    <measurement group_id="O3" value="89" lower_limit="0" upper_limit="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>B/Florida/04/2006, Post-vaccination (0, 187, 190)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA">B/Florida/04/2006 influenza virus antigen was not in the vaccine administered to this group.</measurement>
                    <measurement group_id="O2" value="174" lower_limit="84.0" upper_limit="111"/>
                    <measurement group_id="O3" value="175" lower_limit="0" upper_limit="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Geometric Mean Titers Against the Influenza Vaccine Antigens After Vaccination With Fluzone® Quadrivalent Influenza Vaccine or Trivalent Influenza Vaccines in Adult Participants</title>
        <description>Immunogenicity outcomes were assessed in serum samples by HAI assay. The lower limit of quantitation (LLOQ) was set at the lowest dilution used in the assay, 1/10. Titers below this level were reported as &lt;10.</description>
        <time_frame>21 Days post last vaccination</time_frame>
        <population>Geometric mean titers to influenza vaccine antigens were determined in randomized and vaccinated participants, per-protocol population</population>
        <group_list>
          <group group_id="O1">
            <title>Study Group 1 (2009-2010 Trivalent Influenza Vaccine)</title>
            <description>Participants received the 2009-2010 Trivalent Influenza Vaccine (TIV)</description>
          </group>
          <group group_id="O2">
            <title>Study Group 2 (2008-2009 Trivalent Influenza Vaccine)</title>
            <description>Participants received the 2008-2009 Trivalent Influenza Vaccine (TIV)</description>
          </group>
          <group group_id="O3">
            <title>Study Group 3 (Quadrivalent Influenza Vaccine)</title>
            <description>Participants received the Quadrivalent Influenza Vaccine (QIV)</description>
          </group>
        </group_list>
        <measure>
          <title>Geometric Mean Titers Against the Influenza Vaccine Antigens After Vaccination With Fluzone® Quadrivalent Influenza Vaccine or Trivalent Influenza Vaccines in Adult Participants</title>
          <description>Immunogenicity outcomes were assessed in serum samples by HAI assay. The lower limit of quantitation (LLOQ) was set at the lowest dilution used in the assay, 1/10. Titers below this level were reported as &lt;10.</description>
          <population>Geometric mean titers to influenza vaccine antigens were determined in randomized and vaccinated participants, per-protocol population</population>
          <units>Titers</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="187"/>
                <count group_id="O2" value="188"/>
                <count group_id="O3" value="190"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>A/H1N1, Pre-vaccination (186, 188, 190)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="27.5" lower_limit="22.8" upper_limit="33.0"/>
                    <measurement group_id="O2" value="28.4" lower_limit="23.6" upper_limit="34.3"/>
                    <measurement group_id="O3" value="27.6" lower_limit="22.7" upper_limit="33.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>A/H1N1, Post-vaccination (187, 188, 190)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="145" lower_limit="122" upper_limit="173"/>
                    <measurement group_id="O2" value="157" lower_limit="132" upper_limit="187"/>
                    <measurement group_id="O3" value="161" lower_limit="137" upper_limit="189"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>A/H3N2, Pre-vaccination (186, 188, 190)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="29.9" lower_limit="24.0" upper_limit="37.2"/>
                    <measurement group_id="O2" value="32.7" lower_limit="25.8" upper_limit="41.6"/>
                    <measurement group_id="O3" value="38.5" lower_limit="29.7" upper_limit="49.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>A/H3N2, Post-vaccination (187, 188, 190)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="302" lower_limit="250" upper_limit="365"/>
                    <measurement group_id="O2" value="380" lower_limit="305" upper_limit="472"/>
                    <measurement group_id="O3" value="304" lower_limit="249" upper_limit="370"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>B/Brisbane/60/2008, Pre-vaccination (186, 0, 190)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="22.0" lower_limit="18.5" upper_limit="26.2"/>
                    <measurement group_id="O2" value="NA">B/Brisbane/60/2008 influenza virus antigen not in the vaccine administered to this group.</measurement>
                    <measurement group_id="O3" value="19.9" lower_limit="16.7" upper_limit="23.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>B/Brisbane/60/2008, Post-vaccination (187, 0, 190)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="114" lower_limit="97.8" upper_limit="134"/>
                    <measurement group_id="O2" value="NA">B/Brisbane/60/2008 influenza virus antigen not in the vaccine administered to this group.</measurement>
                    <measurement group_id="O3" value="101" lower_limit="85.6" upper_limit="120"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>B/Florida/04/2006, Pre-vaccination (0, 187, 190)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA">B/Florida/04/2006 influenza virus antigen not in the vaccine administered to this group.</measurement>
                    <measurement group_id="O2" value="32.6" lower_limit="27.4" upper_limit="38.7"/>
                    <measurement group_id="O3" value="27.1" lower_limit="22.5" upper_limit="32.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>B/Florida/04/2006, Post-vaccination (0, 187, 190)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA">B/Florida/04/2006 influenza virus antigen not in the vaccine administered to this group.</measurement>
                    <measurement group_id="O2" value="135" lower_limit="117" upper_limit="156"/>
                    <measurement group_id="O3" value="155" lower_limit="133" upper_limit="180"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Number of Adult Participants With Seroconversion to Vaccine Antigens Following Vaccination With Fluzone® Quadrivalent Influenza Vaccine or Trivalent Influenza Vaccines</title>
        <description>Seroconversion to vaccine antigens was defined as a pre-vaccination titer &lt; 10 (1/dil) and a post-vaccination titer ≥ 40 (1/dil), or a pre-vaccination titer ≥ 10 (1/dil) and a ≥ 4-fold increase in post-vaccination titer.</description>
        <time_frame>Day 21 post-vaccination</time_frame>
        <population>Seroconversion with respect to vaccine antigens were determined in randomized and vaccinated participants, per-protocol population.</population>
        <group_list>
          <group group_id="O1">
            <title>Study Group 1 (2009-2010 Trivalent Influenza Vaccine)</title>
            <description>Participants received the 2009-2010 Trivalent Influenza Vaccine (TIV)</description>
          </group>
          <group group_id="O2">
            <title>Study Group 2 (2008-2009 Trivalent Influenza Vaccine)</title>
            <description>Participants received the 2008-2009 Trivalent Influenza Vaccine (TIV)</description>
          </group>
          <group group_id="O3">
            <title>Study Group 3 (Quadrivalent Influenza Vaccine)</title>
            <description>Participants received the Quadrivalent Influenza Vaccine (QIV)</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Adult Participants With Seroconversion to Vaccine Antigens Following Vaccination With Fluzone® Quadrivalent Influenza Vaccine or Trivalent Influenza Vaccines</title>
          <description>Seroconversion to vaccine antigens was defined as a pre-vaccination titer &lt; 10 (1/dil) and a post-vaccination titer ≥ 40 (1/dil), or a pre-vaccination titer ≥ 10 (1/dil) and a ≥ 4-fold increase in post-vaccination titer.</description>
          <population>Seroconversion with respect to vaccine antigens were determined in randomized and vaccinated participants, per-protocol population.</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="187"/>
                <count group_id="O2" value="188"/>
                <count group_id="O3" value="190"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>A/H1N1 (187, 188, 190)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="103"/>
                    <measurement group_id="O2" value="97" lower_limit="0" upper_limit="0"/>
                    <measurement group_id="O3" value="112" lower_limit="0" upper_limit="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>A/H3N2 (187, 188, 190)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="130"/>
                    <measurement group_id="O2" value="120" lower_limit="0" upper_limit="0"/>
                    <measurement group_id="O3" value="119" lower_limit="0" upper_limit="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>B/Brisbane/60/2008 (187, 0, 190)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="104"/>
                    <measurement group_id="O2" value="NA" lower_limit="0" upper_limit="0">B/Brisbane/60/2008 influenza virus antigen was not in the vaccine administered to this group.</measurement>
                    <measurement group_id="O3" value="101" lower_limit="0" upper_limit="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>B/Florida/04/2006 (0, 188, 190)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA">B/Florida/04/2006 influenza virus antigen was not in the vaccine administered to this group.</measurement>
                    <measurement group_id="O2" value="83" lower_limit="0" upper_limit="0"/>
                    <measurement group_id="O3" value="110" lower_limit="0" upper_limit="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Geometric Mean Titers Against the Influenza Vaccine Antigens After Vaccination With Fluzone® Quadrivalent Influenza Vaccine or Trivalent Influenza Vaccines in All Study Participants</title>
        <description>Immunogenicity outcomes were assessed in serum samples by HAI assay. The lower limit of quantitation (LLOQ) was set at the lowest dilution used in the assay, 1/10. Titers below this level were reported as &lt;10.</description>
        <time_frame>21 Days post last vaccination</time_frame>
        <population>Geometric mean titers to influenza vaccine antigens were determined in randomized and vaccinated participants, per-protocol population</population>
        <group_list>
          <group group_id="O1">
            <title>Study Group 1 (2009-2010 Trivalent Influenza Vaccine)</title>
            <description>Participants received the 2009-2010 Trivalent Influenza Vaccine (TIV)</description>
          </group>
          <group group_id="O2">
            <title>Study Group 2 (2008-2009 Trivalent Influenza Vaccine)</title>
            <description>Participants received the 2008-2009 Trivalent Influenza Vaccine (TIV)</description>
          </group>
          <group group_id="O3">
            <title>Study Group 3 (Quadrivalent Influenza Vaccine)</title>
            <description>Participants received the Quadrivalent Influenza Vaccine (QIV)</description>
          </group>
        </group_list>
        <measure>
          <title>Geometric Mean Titers Against the Influenza Vaccine Antigens After Vaccination With Fluzone® Quadrivalent Influenza Vaccine or Trivalent Influenza Vaccines in All Study Participants</title>
          <description>Immunogenicity outcomes were assessed in serum samples by HAI assay. The lower limit of quantitation (LLOQ) was set at the lowest dilution used in the assay, 1/10. Titers below this level were reported as &lt;10.</description>
          <population>Geometric mean titers to influenza vaccine antigens were determined in randomized and vaccinated participants, per-protocol population</population>
          <units>Titers</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="215"/>
                <count group_id="O2" value="188"/>
                <count group_id="O3" value="189"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>A/H1N1, Pre-vaccination (214, 186, 189)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="27.0" lower_limit="22.8" upper_limit="32.1"/>
                    <measurement group_id="O2" value="27.8" lower_limit="23.1" upper_limit="33.6"/>
                    <measurement group_id="O3" value="25.4" lower_limit="21.0" upper_limit="30.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>A/H1N1, Post-vaccination (214, 187, 189)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="153" lower_limit="131" upper_limit="179"/>
                    <measurement group_id="O2" value="145" lower_limit="123" upper_limit="172"/>
                    <measurement group_id="O3" value="143" lower_limit="122" upper_limit="168"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>A/H3N2, Pre-vaccination (214, 187, 189)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="30.5" lower_limit="25.1" upper_limit="37.2"/>
                    <measurement group_id="O2" value="34.6" lower_limit="27.7" upper_limit="43.3"/>
                    <measurement group_id="O3" value="37.8" lower_limit="29.8" upper_limit="47.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>A/H3N2, Post-vaccination (214, 188, 189)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="285" lower_limit="244" upper_limit="334"/>
                    <measurement group_id="O2" value="330" lower_limit="271" upper_limit="401"/>
                    <measurement group_id="O3" value="263" lower_limit="219" upper_limit="316"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>B/Brisbane/60/2008, Pre-vaccination (214, 0, 189)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15.5" lower_limit="13.4" upper_limit="18.0"/>
                    <measurement group_id="O2" value="NA">B/Brisbane/60/2008 influenza virus antigen was not in vaccine administered to this group.</measurement>
                    <measurement group_id="O3" value="16.2" lower_limit="13.9" upper_limit="18.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>B/Brisbane/60/2008, Post-vaccination (215, 0, 189)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="76.7" lower_limit="66.6" upper_limit="88.4"/>
                    <measurement group_id="O2" value="NA">B/Brisbane/60/2008 influenza virus antigen was not in vaccine administered to this group.</measurement>
                    <measurement group_id="O3" value="75.6" lower_limit="64.8" upper_limit="88.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>B/Florida/04/2006, Pre-vaccination (0, 186, 189)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA">B/Florida/04/2006 influenza virus antigen was not in vaccine administered to this group.</measurement>
                    <measurement group_id="O2" value="26.6" lower_limit="22.8" upper_limit="31.1"/>
                    <measurement group_id="O3" value="21.7" lower_limit="18.3" upper_limit="25.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>B/Florida/04/2006, Post-vaccination (0, 187, 189)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA">B/Florida/04/2006 influenza virus antigen was not in vaccine administered to this group.</measurement>
                    <measurement group_id="O2" value="96.5" lower_limit="84.0" upper_limit="111"/>
                    <measurement group_id="O3" value="109" lower_limit="94.5" upper_limit="125"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Number of Participants With Seroconversion to Influenza Vaccine Antigens Following Vaccination With Fluzone® Quadrivalent Influenza Vaccine or Trivalent Influenza Vaccines</title>
        <description>Seroconversion to vaccine antigens were defined as a pre-vaccination titer &lt; 10 (1/dil) and a post-vaccination titer ≥ 40 (1/dil), or a pre-vaccination titer ≥ 10 (1/dil) and a ≥ 4-fold increase in post-vaccination titer.</description>
        <time_frame>Day 0 up to 21 days post-vaccination</time_frame>
        <population>Seroconversion with respects to influenza vaccine antigens were determined in randomized and vaccinated participants, per-protocol population</population>
        <group_list>
          <group group_id="O1">
            <title>Study Group 1 (2009-2010 Trivalent Influenza Vaccine)</title>
            <description>Participants received the 2009-2010 Trivalent Influenza Vaccine (TIV)</description>
          </group>
          <group group_id="O2">
            <title>Study Group 2 (2008-2009 Trivalent Influenza Vaccine)</title>
            <description>Participants received the 2008-2009 Trivalent Influenza Vaccine (TIV)</description>
          </group>
          <group group_id="O3">
            <title>Study Group 3 (Quadrivalent Influenza Vaccine)</title>
            <description>Participants received the Quadrivalent Influenza Vaccine (QIV)</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Seroconversion to Influenza Vaccine Antigens Following Vaccination With Fluzone® Quadrivalent Influenza Vaccine or Trivalent Influenza Vaccines</title>
          <description>Seroconversion to vaccine antigens were defined as a pre-vaccination titer &lt; 10 (1/dil) and a post-vaccination titer ≥ 40 (1/dil), or a pre-vaccination titer ≥ 10 (1/dil) and a ≥ 4-fold increase in post-vaccination titer.</description>
          <population>Seroconversion with respects to influenza vaccine antigens were determined in randomized and vaccinated participants, per-protocol population</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="215"/>
                <count group_id="O2" value="188"/>
                <count group_id="O3" value="189"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>A/H1N1 Pre-vaccination (214, 186, 189)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="88"/>
                    <measurement group_id="O2" value="71"/>
                    <measurement group_id="O3" value="70"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>A/H1N1 Post-vaccination (213, 186, 189)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="118"/>
                    <measurement group_id="O2" value="90"/>
                    <measurement group_id="O3" value="112"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>A/H3N2 Pre-vaccination (214, 187, 189)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100"/>
                    <measurement group_id="O2" value="94"/>
                    <measurement group_id="O3" value="92"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>A/H3N2 Post-vaccination (213, 187, 189)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="148"/>
                    <measurement group_id="O2" value="119"/>
                    <measurement group_id="O3" value="116"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>B/Brisbane/60/2008 Pre-vaccination (214, 0, 189)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="57"/>
                    <measurement group_id="O2" value="NA">B/Brisbane/60/2008 influenza virus antigen was not in the vaccine administered to this group.</measurement>
                    <measurement group_id="O3" value="50"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>B/Brisbane/60/2008 Post-vaccination (214, 0, 189)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="111"/>
                    <measurement group_id="O2" value="NA">B/Brisbane/60/2008 influenza virus antigen was not in the vaccine administered to this group.</measurement>
                    <measurement group_id="O3" value="99"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>B/Florida/04/2006 Pre-vaccination (0, 186, 189)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA">B/Florida/04/2006 influenza virus antigen was not in the vaccine administered to this group.</measurement>
                    <measurement group_id="O2" value="80"/>
                    <measurement group_id="O3" value="67"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>B/Florida/04/2006 Post-vaccination (0, 186, 189)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA">B/Florida/04/2006 influenza virus antigen was not in the vaccine administered to this group</measurement>
                    <measurement group_id="O2" value="79"/>
                    <measurement group_id="O3" value="100"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Number of Participants With Seroprotection to Influenza Vaccine Antigens Following Vaccination With Fluzone® Quadrivalent Influenza Vaccine or Trivalent Influenza Vaccines</title>
        <description>Immunogenicity outcomes were assessed in serum samples by HAI assay. The lower limit of quantitation (LLOQ) was set at the lowest dilution used in the assay, 1/10. Titers below this level were reported as &lt;10.
Seroprotection to vaccine antigens was defined as a pre-vaccination and post-vaccination titer value of titer ≥ 40 (1/dil).</description>
        <time_frame>Day 0 (pre-vaccination) and Day 21 post final vaccination</time_frame>
        <population>Seroprotection to influenza vaccine antigens were determined in randomized and vaccinated participants, per-protocol population</population>
        <group_list>
          <group group_id="O1">
            <title>Study Group 1 (2009-2010 Trivalent Influenza Vaccine)</title>
            <description>Participants received the 2009-2010 Trivalent Influenza Vaccine (TIV)</description>
          </group>
          <group group_id="O2">
            <title>Study Group 2 (2008-2009 Trivalent Influenza Vaccine)</title>
            <description>Participants received the 2008-2009 Trivalent Influenza Vaccine (TIV)</description>
          </group>
          <group group_id="O3">
            <title>Study Group 3 (Quadrivalent Influenza Vaccine)</title>
            <description>Participants received the Quadrivalent Influenza Vaccine (QIV)</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Seroprotection to Influenza Vaccine Antigens Following Vaccination With Fluzone® Quadrivalent Influenza Vaccine or Trivalent Influenza Vaccines</title>
          <description>Immunogenicity outcomes were assessed in serum samples by HAI assay. The lower limit of quantitation (LLOQ) was set at the lowest dilution used in the assay, 1/10. Titers below this level were reported as &lt;10.
Seroprotection to vaccine antigens was defined as a pre-vaccination and post-vaccination titer value of titer ≥ 40 (1/dil).</description>
          <population>Seroprotection to influenza vaccine antigens were determined in randomized and vaccinated participants, per-protocol population</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="215"/>
                <count group_id="O2" value="188"/>
                <count group_id="O3" value="189"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>A/H1N1, Pre-vaccination (214, 186, 189)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="88"/>
                    <measurement group_id="O2" value="71"/>
                    <measurement group_id="O3" value="70"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>A/H1N1, Post-vaccination (214, 187, 189)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="193"/>
                    <measurement group_id="O2" value="168"/>
                    <measurement group_id="O3" value="169"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>A/H3N2, Pre-vaccination (214, 187, 189)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100"/>
                    <measurement group_id="O2" value="94"/>
                    <measurement group_id="O3" value="92"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>A/H3N2, Post-vaccination (214, 188, 189)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="209"/>
                    <measurement group_id="O2" value="179"/>
                    <measurement group_id="O3" value="179"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>B/Brisbane/60/2008, Pre-vaccination (214, 0, 189)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="57"/>
                    <measurement group_id="O2" value="NA">B/Brisbane/60/2008 influenza virus antigen was not in the vaccine administered to this group.</measurement>
                    <measurement group_id="O3" value="50"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>B/Brisbane/60/2008, Post-vaccination (215, 0, 189)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="172"/>
                    <measurement group_id="O2" value="NA">B/Brisbane/60/2008 influenza virus antigen was not in the vaccine administered to this group.</measurement>
                    <measurement group_id="O3" value="153"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>B/Florida/04/2006, Pre-vaccination (0, 186, 189)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA">B/Florida/04/2006 influenza virus antigen was not in the vaccine administered to this group.</measurement>
                    <measurement group_id="O2" value="80"/>
                    <measurement group_id="O3" value="67"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>B/Florida/04/2006, Post-vaccination (0, 187, 189)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA">B/Florida/04/2006 influenza virus antigen was not in the vaccine administered to this group.</measurement>
                    <measurement group_id="O2" value="164"/>
                    <measurement group_id="O3" value="169"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Geometric Mean Titers (GMTs) Against Influenza A Strains After Vaccination With Fluzone® Quadrivalent Influenza Vaccine or Trivalent Influenza Vaccine in Adult Participants.</title>
        <description>Immunogenicity outcomes were assessed in serum samples by Hemagglutination inhibition (HAI) assay. The lower limit of quantitation (LLOQ) was set at the lowest dilution used in the assay, 1/10. Titers below this level were reported as &lt;10.</description>
        <time_frame>21 Days post last vaccination</time_frame>
        <population>Geometric mean titers to vaccine A strains were determined in the per-protocol population. For this outcome, the data for the A/Brisbane/59/2007(A1N1) and A/Uruguay/716/2007(H3N2) antibodies were pooled for participants vaccinated with either 2009-2010 TIV or 2008-2009 TIV and presented in the column for Study Group 1 (2009-2010 TIV).</population>
        <group_list>
          <group group_id="O1">
            <title>Study Group 1 (2009-2010 Trivalent Influenza Vaccine)</title>
            <description>Participants received the 2009-2010 Trivalent Influenza Vaccine (TIV)</description>
          </group>
          <group group_id="O2">
            <title>Study Group 2 (2008-2009 Trivalent Influenza Vaccine)</title>
            <description>Participants received the 2008-2009 Trivalent Influenza Vaccine (TIV)</description>
          </group>
          <group group_id="O3">
            <title>Study Group 3 (Quadrivalent Influenza Vaccine)</title>
            <description>Participants received the Quadrivalent Influenza Vaccine (QIV)</description>
          </group>
        </group_list>
        <measure>
          <title>Geometric Mean Titers (GMTs) Against Influenza A Strains After Vaccination With Fluzone® Quadrivalent Influenza Vaccine or Trivalent Influenza Vaccine in Adult Participants.</title>
          <description>Immunogenicity outcomes were assessed in serum samples by Hemagglutination inhibition (HAI) assay. The lower limit of quantitation (LLOQ) was set at the lowest dilution used in the assay, 1/10. Titers below this level were reported as &lt;10.</description>
          <population>Geometric mean titers to vaccine A strains were determined in the per-protocol population. For this outcome, the data for the A/Brisbane/59/2007(A1N1) and A/Uruguay/716/2007(H3N2) antibodies were pooled for participants vaccinated with either 2009-2010 TIV or 2008-2009 TIV and presented in the column for Study Group 1 (2009-2010 TIV).</population>
          <units>Titers</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="375"/>
                <count group_id="O2" value="0"/>
                <count group_id="O3" value="190"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>A/Brisbane/59/2007(A1N1) [N = 375, 0, 190]</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="151" lower_limit="134" upper_limit="171"/>
                    <measurement group_id="O3" value="161" lower_limit="137" upper_limit="189"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>A/Uruguay/716/2007(H3N2) [N = 375, 0, 190]</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="339" lower_limit="239" upper_limit="392"/>
                    <measurement group_id="O3" value="304" lower_limit="249" upper_limit="370"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Adverse events data were collected from the day of vaccination (Day 0) up to 28 days post-vaccination</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Study Group 1 (2009-2010 Trivalent Influenza Vaccine)</title>
          <description>Participants received the 2009-2010 Trivalent Influenza Vaccine (TIV)</description>
        </group>
        <group group_id="E2">
          <title>Study Group 2 (2008-2009 Trivalent Influenza Vaccine)</title>
          <description>Participants received the 2008-2009 Trivalent Influenza Vaccine (TIV)</description>
        </group>
        <group group_id="E3">
          <title>Study Group 3 (Quadrivalent Influenza Vaccine)</title>
          <description>Participants received the Quadrivalent Influenza Vaccine (QIV)</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA version 12.0</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="220"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="190"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="190"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Vertigo positional</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="220"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="190"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Chest pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="220"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="190"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5.00</frequency_threshold>
        <default_vocab>MedDRA version 12.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="105" subjects_at_risk="220"/>
                <counts group_id="E2" subjects_affected="84" subjects_at_risk="190"/>
                <counts group_id="E3" subjects_affected="91" subjects_at_risk="190"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Pyrexia</sub_title>
                <assessment>Non-systematic Assessment</assessment>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="30"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Injection site Pain</sub_title>
                <counts group_id="E1" events="105" subjects_affected="105" subjects_at_risk="215"/>
                <counts group_id="E2" events="82" subjects_affected="82" subjects_at_risk="190"/>
                <counts group_id="E3" events="90" subjects_affected="90" subjects_at_risk="190"/>
              </event>
              <event>
                <sub_title>Malaise</sub_title>
                <counts group_id="E1" events="30" subjects_affected="30" subjects_at_risk="220"/>
                <counts group_id="E2" events="23" subjects_affected="23" subjects_at_risk="190"/>
                <counts group_id="E3" events="20" subjects_affected="20" subjects_at_risk="190"/>
              </event>
              <event>
                <sub_title>Shivering</sub_title>
                <counts group_id="E1" events="10" subjects_affected="10" subjects_at_risk="190"/>
                <counts group_id="E2" events="6" subjects_affected="6" subjects_at_risk="190"/>
                <counts group_id="E3" events="5" subjects_affected="5" subjects_at_risk="190"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Appetite lost</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Myalgia</sub_title>
                <counts group_id="E1" events="50" subjects_affected="50" subjects_at_risk="220"/>
                <counts group_id="E2" events="32" subjects_affected="32" subjects_at_risk="190"/>
                <counts group_id="E3" events="45" subjects_affected="45" subjects_at_risk="190"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <assessment>Non-systematic Assessment</assessment>
                <counts group_id="E1" events="12" subjects_affected="10" subjects_at_risk="190"/>
                <counts group_id="E2" events="10" subjects_affected="10" subjects_at_risk="190"/>
                <counts group_id="E3" events="5" subjects_affected="5" subjects_at_risk="190"/>
              </event>
              <event>
                <sub_title>Drowsiness</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="15"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="35" subjects_affected="35" subjects_at_risk="220"/>
                <counts group_id="E2" events="34" subjects_affected="34" subjects_at_risk="190"/>
                <counts group_id="E3" events="30" subjects_affected="30" subjects_at_risk="190"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Crying abnormal</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Irritability</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Cough</sub_title>
                <assessment>Non-systematic Assessment</assessment>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="30"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Rhinorrhoea</sub_title>
                <assessment>Non-systematic Assessment</assessment>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="30"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Rash</sub_title>
                <assessment>Non-systematic Assessment</assessment>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="30"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>Sponsor must have the opportunity to review at least 60 days prior to submission for publication or presentation. If review indicates that potentially patentable subject matter would be disclosed, publication or public disclosure may be delayed for a maximum of an additional 60 days to allow for filing the necessary patent applications</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Medical Director</name_or_title>
      <organization>Sanofi Pasteur Inc.</organization>
      <email>RegistryContactUs@sanofipasteur.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

